- Home
- TDS vs EWTX Comparison
TDS vs EWTX Comparison
Compare TDS & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TDS | EWTX |
|---|---|---|
| Founded | 1968 | 2017 |
| Country | United States | United States |
| Employees | N/A | 127 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.3B |
| IPO Year | 1997 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TDS | EWTX |
|---|---|---|
| Price | $34.82 | $39.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $53.33 | $39.00 |
| AVG Volume (30 Days) | ★ 1.2M | 1.2M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | ★ 23.53 | N/A |
| EPS | ★ 3.50 | N/A |
| Revenue | ★ $1,228,207,000.00 | N/A |
| Revenue This Year | $4.05 | N/A |
| Revenue Next Year | $1.72 | N/A |
| P/E Ratio | $10.27 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $31.51 | $14.25 |
| 52 Week High | $49.12 | $48.51 |
Technical Indicators
Market Signals| Indicator | TDS | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.71 | 39.48 |
| Support Level | $33.01 | $37.50 |
| Resistance Level | $36.57 | $41.04 |
| Average True Range (ATR) | 0.96 | 2.14 |
| MACD | -0.23 | -0.61 |
| Stochastic Oscillator | 9.79 | 13.88 |
Price Performance
Historical ComparisonAbout TDS Telephone and Data Systems Inc.
Telephone and Data Systems Inc is a diversified telecommunications operator that provides communications services to customers through broadband, video, voice, and wireless connections. The company has two reportable segments: TDS Telecom and Array. The majority of its revenue is generated from the TDS Telecom segment, which generates revenue by providing broadband, video, voice, and wireless services. The Array segment generates its revenue mainly by leasing tower space on Array-owned towers to customers.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.